The Israel-based startup now has $50 million in funding to expand its solutions and clinical research as well as support global implementation of its solutions.
Medial EarlySign’s technologies include AI- and machine learning-based clinical decision support solutions for healthcare providers and laboratories as well as custom solutions targeted toward disease-specific patient management. Its solutions are being tested in clinical data studies involving 20 million-plus patients, according to the report.
More articles on artificial intelligence:
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
